Difference between revisions of "Resource:69dad1bb-9632-43ed-b3c1-c49a1fcd8910"
From The Embassy of Good Science
Marc.VanHoof (talk | contribs) |
Marc.VanHoof (talk | contribs) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{Resource | {{Resource | ||
|Resource Type=Cases | |Resource Type=Cases | ||
| − | |Title= | + | |Title=Industry involvement in scientific studies on SSRI's |
| − | |Is About=This case is about scientific fraud in research concerning psychopharmacology. | + | |Is About=This case is about scientific fraud in research concerning psychopharmacology. Specifically, it is about the use of the selective serotonin reuptake inhibitor (SSRI) group of antidepressants that has the potential to trigger suicidality in a subgroup of patients. This is a factual case, linked to companies' abilties to keep clinical trial data out of the public domain. |
| − | |||
| − | |||
| − | This is a factual case. | ||
|Important Because=The outcome of such research affects the lives of many patiens who use the SSRI's. | |Important Because=The outcome of such research affects the lives of many patiens who use the SSRI's. | ||
| − | + | |Important For=Researchers; research integrity researchers; Early career researchers; Ethics committee members | |
| − | |||
| − | |||
| − | |Important For=Researchers | ||
}} | }} | ||
{{Link | {{Link | ||
|Has Link=https://link.springer.com/article/10.1007/s11948-003-0020-2 | |Has Link=https://link.springer.com/article/10.1007/s11948-003-0020-2 | ||
}} | }} | ||
| − | {{Related To}} | + | {{Related To |
| + | |Related To Resource=Resource:4d39f067-fb71-4d6b-b33b-3c27f0bd6414;Resource:Bbcc248c-0ac3-4405-a35b-67e2c34ea571;Resource:Bdaacb81-740f-4483-b0b5-870701ef887a | ||
| + | |Related To Theme=Theme:047c3bec-1747-499b-b6d5-684cbfb81edd;Theme:5f65272f-6e95-4768-8236-bc821a97f3d8 | ||
| + | }} | ||
{{Tags | {{Tags | ||
| − | |Involves= | + | |Involves=Pfizer; University of Toronto |
|Has Timepoint=1990 | |Has Timepoint=1990 | ||
|Has Location=Canada | |Has Location=Canada | ||
Latest revision as of 18:43, 25 October 2020
ResourcesCases
Industry involvement in scientific studies on SSRI's
What is this about?
This case is about scientific fraud in research concerning psychopharmacology. Specifically, it is about the use of the selective serotonin reuptake inhibitor (SSRI) group of antidepressants that has the potential to trigger suicidality in a subgroup of patients. This is a factual case, linked to companies' abilties to keep clinical trial data out of the public domain.
Why is this important?
The outcome of such research affects the lives of many patiens who use the SSRI's.
